FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076280173> ?p ?o ?g. }

• W2076280173 endingPage "75" @default.
• W2076280173 startingPage "68" @default.
• W2076280173 abstract "Vascular restenosis is affecting 30-40% of patients treated by percutaneous coronary angioplasty (PTCA). The advent of stenting reduced but not abolished restenosis. The introduction of drug eluting stent (DES) further reduced restenosis, but impaired endothelization exposed to intracoronary thrombosis as late adverse event. It is widely accepted that the endothelial denudation and coronary wall damages expose Vascular Smooth Muscle Cells (VSMC) to multiple growth factors and plasma circulating agents thus activating migration and proliferative pathways leading to restenosis. Among the major players of this processes, phosphorylated Elk-1, forming the Elk-1/SRF transcription complex, controls the expression of a different set of genes responsible for cell proliferation. Therefore, it is feasible that gene-specific oligonucleotide therapy targeting VSMC migration and proliferation genes can be a promising therapeutic approach. While a plethora of vehicles is suitably working in static in vitro cultures, methods for in vivo delivery of oligonucleotides are still under investigation. Recently, we have patented a novel erythrocyte-based drug delivery system with high capability to fuse with targeted cells thus improving drug bioavailability at the site of action. Here, the potential of these engineered porcine erythrocytes to deliver a synthetic DNA Elk-1 decoy inside syngenic porcine VSMC was tested. The results of this study indicate that Elk-1 decoy is actually able to inhibit cell proliferation and migration of VSMC. Our data also suggest that erythrocyte-based carriers are more efficient in delivering these oligonucleotides in comparison to conventional vehicles. As a consequence, a lower dose of Elk-1 decoy, delivered by engineered erythrocytes, was sufficient to inhibit cell growth and migration. This approach represents the translational step to reach in vivo experiments in pigs after PTCA and/or stent implantation where oligonucleotide drugs will be site-specific administered by using erythrocyte-based carriers to prevent restenosis. Keywords: Vascular Smooth Muscle Cells, DNA Oligonucleotide decoy, gene therapy, erythrocyte-based drug delivery system, target therapy, biotherapy delivery, endothelial layer, hyperplasia" @default.
• W2076280173 created "2016-06-24" @default.
• W2076280173 creator A5003384865 @default.
• W2076280173 creator A5018034749 @default.
• W2076280173 creator A5031208365 @default.
• W2076280173 creator A5032677400 @default.
• W2076280173 creator A5039981200 @default.
• W2076280173 creator A5080680689 @default.
• W2076280173 creator A5084895786 @default.
• W2076280173 creator A5085271923 @default.
• W2076280173 creator A5086972795 @default.
• W2076280173 date "2012-07-01" @default.
• W2076280173 modified "2023-09-26" @default.
• W2076280173 title "Innovative Erythrocyte-based Carriers for Gene Delivery in Porcine Vascular Smooth Muscle Cells: Basis for Local Therapy to Prevent Restenosis" @default.
• W2076280173 cites W150846722 @default.
• W2076280173 cites W157017159 @default.
• W2076280173 cites W1927732700 @default.
• W2076280173 cites W1971177181 @default.
• W2076280173 cites W1973458116 @default.
• W2076280173 cites W2008988352 @default.
• W2076280173 cites W2013470095 @default.
• W2076280173 cites W2030548928 @default.
• W2076280173 cites W2038884731 @default.
• W2076280173 cites W2056966258 @default.
• W2076280173 cites W2063220206 @default.
• W2076280173 cites W2066411052 @default.
• W2076280173 cites W2072949048 @default.
• W2076280173 cites W2091039183 @default.
• W2076280173 cites W2091087233 @default.
• W2076280173 cites W2092482435 @default.
• W2076280173 cites W2093379612 @default.
• W2076280173 cites W2102209691 @default.
• W2076280173 cites W2106059849 @default.
• W2076280173 cites W2107505404 @default.
• W2076280173 cites W2113693222 @default.
• W2076280173 cites W2119339513 @default.
• W2076280173 cites W2121892940 @default.
• W2076280173 cites W2123912943 @default.
• W2076280173 cites W2137947914 @default.
• W2076280173 cites W2140333493 @default.
• W2076280173 cites W2142286991 @default.
• W2076280173 cites W2143022774 @default.
• W2076280173 cites W2165465921 @default.
• W2076280173 cites W2167084322 @default.
• W2076280173 cites W2315357980 @default.
• W2076280173 cites W2409809330 @default.
• W2076280173 cites W2468153757 @default.
• W2076280173 cites W3022305634 @default.
• W2076280173 cites W56272860 @default.
• W2076280173 doi "https://doi.org/10.2174/187152912801823101" @default.
• W2076280173 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22746344" @default.
• W2076280173 hasPublicationYear "2012" @default.
• W2076280173 type Work @default.
• W2076280173 sameAs 2076280173 @default.
• W2076280173 citedByCount "9" @default.
• W2076280173 countsByYear W20762801732013 @default.
• W2076280173 countsByYear W20762801732014 @default.
• W2076280173 countsByYear W20762801732015 @default.
• W2076280173 countsByYear W20762801732020 @default.
• W2076280173 countsByYear W20762801732021 @default.
• W2076280173 countsByYear W20762801732022 @default.
• W2076280173 crossrefType "journal-article" @default.
• W2076280173 hasAuthorship W2076280173A5003384865 @default.
• W2076280173 hasAuthorship W2076280173A5018034749 @default.
• W2076280173 hasAuthorship W2076280173A5031208365 @default.
• W2076280173 hasAuthorship W2076280173A5032677400 @default.
• W2076280173 hasAuthorship W2076280173A5039981200 @default.
• W2076280173 hasAuthorship W2076280173A5080680689 @default.
• W2076280173 hasAuthorship W2076280173A5084895786 @default.
• W2076280173 hasAuthorship W2076280173A5085271923 @default.
• W2076280173 hasAuthorship W2076280173A5086972795 @default.
• W2076280173 hasConcept C104317684 @default.
• W2076280173 hasConcept C111599444 @default.
• W2076280173 hasConcept C126322002 @default.
• W2076280173 hasConcept C135983454 @default.
• W2076280173 hasConcept C170493617 @default.
• W2076280173 hasConcept C2778283817 @default.
• W2076280173 hasConcept C2778583881 @default.
• W2076280173 hasConcept C2779179475 @default.
• W2076280173 hasConcept C2779395532 @default.
• W2076280173 hasConcept C2992686903 @default.
• W2076280173 hasConcept C55493867 @default.
• W2076280173 hasConcept C71924100 @default.
• W2076280173 hasConcept C86803240 @default.
• W2076280173 hasConcept C95444343 @default.
• W2076280173 hasConcept C98274493 @default.
• W2076280173 hasConceptScore W2076280173C104317684 @default.
• W2076280173 hasConceptScore W2076280173C111599444 @default.
• W2076280173 hasConceptScore W2076280173C126322002 @default.
• W2076280173 hasConceptScore W2076280173C135983454 @default.
• W2076280173 hasConceptScore W2076280173C170493617 @default.
• W2076280173 hasConceptScore W2076280173C2778283817 @default.
• W2076280173 hasConceptScore W2076280173C2778583881 @default.
• W2076280173 hasConceptScore W2076280173C2779179475 @default.
• W2076280173 hasConceptScore W2076280173C2779395532 @default.
• W2076280173 hasConceptScore W2076280173C2992686903 @default.
• W2076280173 hasConceptScore W2076280173C55493867 @default.
• W2076280173 hasConceptScore W2076280173C71924100 @default.

• next